Follow
M.I. Mas-Fuster
M.I. Mas-Fuster
Verified email at umh.es
Title
Cited by
Cited by
Year
Importance of standardizing the dose in hyperthermic intraperitoneal chemotherapy (HIPEC): a pharmacodynamic point of view
MI Mas-Fuster, A Ramon-Lopez, R Nalda-Molina
Cancer chemotherapy and pharmacology 72, 273-274, 2013
182013
Population pharmacokinetics of oxaliplatin after intraperitoneal administration with hyperthermia in Wistar rats
MI Mas-Fuster, A Ramon-Lopez, FJ Lacueva, A Arroyo, P Más-Serrano, ...
European Journal of Pharmaceutical Sciences 119, 22-30, 2018
72018
Impact of Laparotomy and Intraperitoneal Hyperthermic Instillation (LIHI) on the oxaliplatin pharmacokinetics after intravenous administration in Wistar rats
MI Mas-Fuster, A Ramon-Lopez, J Lacueva, A Compań, P Más-Serrano, ...
Cancer chemotherapy and pharmacology 79, 621-627, 2017
22017
Suitability of the AUC Ratio as an Indicator of the Pharmacokinetic Advantage in HIPEC
MI Mas-Fuster, A Ramon-Lopez, J Lacueva, P Más-Serrano, ...
Journal of Pharmaceutical Sciences 107 (2), 764-769, 2018
2018
Population Pharmacokinetics of Hyperthermic Intraoperative Peritoneal Oxaliplatin in Wistar Rats
A Ramón-López, MI Mas-Fuster, FJ Lacueva, P Más-Serrano, ...
The system can't perform the operation now. Try again later.
Articles 1–5